Patents by Inventor Sergey AKSENOV

Sergey AKSENOV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF VEGF ANTAGONIST IN TREATING CHORIORETINAL NEOVASCULAR AND PERMEABILITY DISORDERS IN PAEDIATRIC PATIENTS
    Publication number: 20180194835
    Abstract: The present invention relates to the use of a VEGF antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a VEGF antagonist for use in a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops. The invention further provides the use of a VEGF antagonist in the manufacture of a medicament for treating a child having a chorioretinal neovascular or permeability disorder.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 12, 2018
    Inventors: Gabriela Burian, Sergey AKSENOV
  • USE OF VEGF ANTAGONIST IN TREATING CHORIORETINAL NEOVASCULAR AND PERMEABILITY DISORDERS IN PAEDIATRIC PATIENTS
    Publication number: 20160168240
    Abstract: The present invention relates to the use of a VEGF antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a VEGF antagonist for use in a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops. The invention further provides the use of a VEGF antagonist in the manufacture of a medicament for treating a child having a chorioretinal neovascular or permeability disorder.
    Type: Application
    Filed: July 9, 2014
    Publication date: June 16, 2016
    Inventors: Sergey AKSENOV, Gabriela BURIAN
  • Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
    Publication number: 20160159893
    Abstract: The present invention relates to the use of a VEGF antagonist in the treatment of retinal neovascular disorders in infants. In particular, the invention provides a method for treating an infant having retinopathy of prematurity (ROP), wherein said method comprises administering to the eye of an infant a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The term “infant” is typically used to refer to young children from birth up to the age of 12 months. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops.
    Type: Application
    Filed: July 10, 2014
    Publication date: June 9, 2016
    Inventors: Gabriela BURIAN, Sergey AKSENOV